Prof Fizazi (Institut Gustave Roussy, Paris, France), Prof Miller (Benjamin Franklin University Clinic, Berlin, Germany), Dr De Santis (Kaiser Franz Josef Hospital, Vienna, Austria) and Dr Rubin (Cornell University, New York, USA) for ecancertv about the data and opinions arising on prostate cancer from Day One at ASCO GU 2015.
Prof Stephane Oudard (Georges Pompidou Hospital, Paris, France) and Prof Noel Clarke (The Christie Hospital, Manchester, UK) discuss the implications of negative trial results with ecancertv at ASCO GU 2015 with special focus on the following abstracts: COMET-1: Cabozantinib versus prednisone in metastatic castration-resistant prostate cancer patients previously treated with docetaxel and abiraterone and/or enzalutamide. COMET-2 Final analysis of COMET-2: Cabozantinib versus mitoxantrone/prednisone in metastatic castration-resistant prostate cancer patients with moderate to severe pain who were previously treated with docetaxel and abiraterone and/or enzalutamide. Androgen deprivation therapy plus docetaxel versus ADT alone for hormone-naïve metastatic prostate cancer: Long-term analysis of the GETUG-AFU 15 phase III trial.
Dr Naomi Balzer-Haas talks to ecancertv at ASCO GU 2015 about the initial results from the phase III ASSURE trial. It appears that adjuvant sorafenib or sunitinib do not benefit patients with unfavourable locally advanced renal carcinoma, but these findings raise more questions.
Dr Parker talks to ecancertv at ASCO GU 2015 about some of the most interesting and provocative research in genitourinary cancers emerging from the symposium. He addresses the ASCENDE-RT trial, comparing external beam therapy vs. brachyotherapy, discusses the update of the GETUG-15 trial, and touches on the controversial and exciting results of the MCR-PR07 trial on statins.
Dr Mark Beresford talks to ecancertv at ASCO GU 2015 reflecting on the initial results of the ASSURE trial where adjuvant treatment with sorafenib or sunitinib is used for localised renal carcinoma. Neither sorafenib nor sunitinib provide improved outcomes. Other trials such as SORCE which looks at sorafenib and ATLAS which looks at axitinib question the duration of treatment.
Dr Voss talks to ecancertv at ASCO GU 2015 on part 1 of the DART Study, a phase II randomised trial using dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma. Results have shown that the combination of dalantercept and axitinib is well tolerated and demonstrated and associated with encouraging activity in patients with prior VEGF, mTOR, and immune therapies.
Dr McKay talks to ecancertv at ASCO GU 2015 about the results of a phase II trial of sunitinib and gemcitabine in sarcomatoid and/or poor-risk patients with metastatic renal cell carcinoma.
Dr Gwenaëlle Gravis talks to ecancertv at ASCO GU 2015 about the results of the GETUG-AFU 15 phase III trial. Long-term follow-up results suggest that the addition of docetaxel to androgen deprivation therapy did not significantly improve overall survival in patients with hormone-naïve metastatic prostate cancer.
Dr McKay talks to ecancertv at ASCO GU 2015 about her work looking at the use of statins as a potential life-extending adjunct therapeutic option for patients with metastatic renal cell carcinoma.
Urinary bladder urothelial carcinoma is a devastating disease with extremely limited treatment options - how can we find new drug targets for it? Dr Jeffrey Ross talks to ecancertv at ASCO GU 2015 about his work on the genomic profiling of bladder carcinoma, looking for genetic alterations that will give clues for future treatments.
Dr Emmanuel Antonarakis talks to ecancertv at ASCO GU 15 about the results of his small prospective study on the correlation between androgen receptor V7 status and resistance to taxane chemotherapy in men with metastatic castration-resistant prostate cancer.
Dr Joaquin Mateo speaks to ecancertv at ASCO GU 2015 following results from the Phase II trial using abiraterone and cabazitaxel combination in metastatic castration-resistant prostate cancer where it's found to be well tolerated and demonstrated antitumor activity in the post-docetaxel, post-abiraterone setting.
Prof Galsky talks to ecancertv at ASCO GU 2015 about the effectiveness of adjuvant chemotherapy in patients with bladder cancer; his findings suggest that adjuvant chemotherapy is effective.
Dr Punnen talks to ecancertv at ASCO GU 2015 about prostate screening and risk assessment - should people receive treatment when they wouldn't live long enough to be affected by their cancer? Should they even be biopsied in the first place?
Prof Powles talks to ecancertv at ASCO GU 2015 about the use of dual TORC1 and 2 inhibitors, such as AZD2014, in the treatment of renal cancer.
Dr Tyldesley talks to ecancertv at ASCO GU 2015 about his work looking at dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) to treat men with unfavourable-risk localised prostate cancer.
Dr Thomsen talks to ecancertv at ASCO GU 2015 about his work looking at bicalutamide 150 mg daily versus placebo in hormone-naïve, non-metastatic prostate cancer.
Prof Srinivas talks to ecancertv at ASCO GU 2015 about the results of a phase II study which looked at the use of pazopanib with weekly paclitaxel in refractory urothelial cancer.
Prof Figlin talks to ecancertv at ASCO GU 2015 about the use of sunitinib in renal cancer when combined with AGS-003, an autologous immunotherapy designed to induce an immune response to a patient’s own tumour.
Prof Nabid talks to ecancertv at ASCO GU 2015 about the results of a phase III study examining the "controversial" role of short-term androgen deprivation therapy in intermediate-risk prostate cancer treated with radiotherapy.